New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics
Welcome to the September 2016 issue of PharmSource PERISCOPE
This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.
Enjoy the September issue!
PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity
|Lead Type||August 2016||YTD 2016|
|Total Drug Leads||368||2980|
|Total Device &
*Total leads include acquisitions/alliances, company acquisition/alliances and events.
Axsome Therapeutics plans to initiate a Phase II/III clinical trial with AXS-05 for the treatment of agitation in patients with Alzheimer’s disease:
- Therapeutic Area: Alzheimer’s disease/Dementia
- Dosage Form: Oral
- API: Chemical – Normal potency
Get deeper information about the likely upcoming needs of Axsome, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
FDA Breakthrough Therapy Designation and EMA PRIME Status
by Scotty Chung-Siu, Research Analyst
The PharmSource Lead Sheet continues to be an excellent source of valuable information on drug candidates that have been granted expedited development and review programs through the FDA and EMA, such as Orphan Drug Designation and Fast Track Designation.
We are excited to announce that the PharmSource Lead Sheet now provides information on FDA Breakthrough Therapy Designation in the US and EMA PRIME status in Europe.
Companies applying for this designation must meet two criteria for the drug… read on
Will the dose CMO industry recover from a disappointing year?
Follow the Money to
Spotlight on OncoMed Pharmaceuticals, Inc.
OncoMed is a U.S. public biopharmaceutical company that discovers and develops mAbs and small molecules for the treatment of cancer. They raised $59.2 million in a secondary public offering.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support R&D efforts of its pipeline, possibly including… read on
Follow the Money to
Medical Device & Diagnostic Opportunities
Spotlight on CVRx, Inc.
CVRx is a U.S. private company that develops proprietary technologies for the treatment of high blood pressure and heart failure. They raised $113 million in a completion of a mixed financing round, which included $93 million in equity financing and a $20 million debt facility.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the following clinical trial… read on
PharmSource President Jim Miller to Speak at Two Industry Events
Contract Pharma: 15th Annual Conference and Tabletop Exhibition.
New Brunswick, New Jersey
Thursday, September 22 at 1:30 pm
CPhI Worldwide: 8th Pre-Connect Congress.
Monday, October 3 at 10 am
PharmSource is pleased to be a media partner with Partnerships in Clinical Trials 2016. This event will address clinical trials outsourcing, procurement, operations and innovation, as well as disruptive technologies that can make trials faster, better and more cost-effective.
Date: October 5 to October 7
Location: Boston, MA, USA
Celebrating 20 Years in Business!
Thank you to our clients, colleagues and friends. We look forward to many more years of successful business together.
PharmSource Lead Sheet
The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.
Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.
See for yourself how this resource can be a vital tool for building your brand and growing your market share.
To request a test-drive today, contact Nathaniel Celentano at email@example.com / 1-703-383-4903, ext. 112 (ET USA).